Oxybutynin chloride (BioDeep_00000743067)

   


代谢物信息卡片


Oxybutynin chloride

化学式: C22H32ClNO3 (393.2070592)
中文名称: 盐酸奥昔布宁
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl
InChI: 1H

描述信息

C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics
D000890 - Anti-Infective Agents > D000892 - Anti-Infective Agents, Urinary > D008333 - Mandelic Acids
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
D000089162 - Genitourinary Agents > D064804 - Urological Agents
Oxybutynin chloride is an oral active and competitive mAChR antagonist with Kis of 14.3 and 5.55 nM for specific [3H]NMS binding in the mouse bladder and cerebral cortex, respectively. Oxybutynin chloride inhibits vascular Kv channels in a manner independent of anticholinergic effect, with an IC50 value of 11.51 μM. Oxybutynin chloride reduces muscle spasm in the bladder and urinary tract, can be used in study of overactive bladder syndrome (OAB)[1][2]. Oxybutynin (chloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

同义名列表

2 个代谢物同义名

Oxybutynin chloride; Oxybutynin (chloride)



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Lorena M D Cirino, Daviane M C Vergne, Gabrielle B Novais, Amanda Cano, Francine F Padilha, Patrícia Severino, Ricardo L C de Albuquerque Júnior, Juliana C Cardoso, Eliana B Souto. Liposomal formulations of oxybutynin and resiniferatoxin for the treatment of urinary diseases: improvement of drug tolerance upon intravesical. Drug delivery and translational research. 2022 07; 12(7):1738-1752. doi: 10.1007/s13346-021-01082-6. [PMID: 34671947]
  • Yuze Sheng, Shuang Zhang, Jiawei Ling, Chenlu Hu, Zhenhai Zhang, Huixia Lv. Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome. Pharmaceutical development and technology. 2022 Apr; 27(4):459-468. doi: 10.1080/10837450.2022.2078983. [PMID: 35575444]
  • Toshiro Suzuki, Tomonori Minagawa, Tetsuichi Saito, Tatsuo Nakagawa, Tomio Suzuki, Masayuki Furuhata, Kyoko Hosaka, Teruyuki Ogawa, Osamu Ishizuka. Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial. International journal of urology : official journal of the Japanese Urological Association. 2021 Sep; 28(9):944-949. doi: 10.1111/iju.14608. [PMID: 34053119]
  • Ali Gözüküçük, Mehmet Kılıç, Basri Çakıroğlu. Desmopressin versus desmopressin + oxybutynin in the treatment of children with nocturnal enuresis. Journal of pediatric urology. 2021 08; 17(4):451.e1-451.e6. doi: 10.1016/j.jpurol.2021.04.001. [PMID: 33931318]
  • Matthew S Lee, Mark Assmus, Deepak Agarwal, Marcelino E Rivera, Tim Large, Amy E Krambeck. Opioid Free Ureteroscopy: What is the True Failure Rate?. Urology. 2021 08; 154(?):89-95. doi: 10.1016/j.urology.2021.03.011. [PMID: 33774043]
  • Melanie Kretschmar, Ahmed Abbas Suleiman, Petra Krause, Uwe Albrecht, Raimund Stein, Peter Rubenwolf, Uwe Fuhr, Max Taubert. A Population Pharmacokinetic Model of (R)- and (S-) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers. Journal of clinical pharmacology. 2021 07; 61(7):961-971. doi: 10.1002/jcph.1809. [PMID: 33368382]
  • Koosha Kamali, Javad Nikbakht, Erfan Ayubi, Mostafa Nabizadeh, Saeedeh Sarhadi. Comparison of the Efficacy of Oxybutynin, Phenazopyridine, Celecoxib, and Placebo in the Treatment of Urinary Tract Symptoms after BCG Therapy in Patients with Bladder Tumors. Urology journal. 2020 Sep; 18(4):439-444. doi: 10.22037/uj.v16i7.5947. [PMID: 32981029]
  • Ahmed Abdelhalim, Ahmed S El-Hefnawy, Mohamed E Dawaba, Mahmoud A Bazeed, Ashraf T Hafez. Effect of Early Oxybutynin Treatment on Posterior Urethral Valve Outcomes in Infants: A Randomized Controlled Trial. The Journal of urology. 2020 04; 203(4):826-831. doi: 10.1097/ju.0000000000000691. [PMID: 31821098]
  • Hongliang Li, Mi Seon Seo, Jin Ryeol An, Hee Seok Jung, Kwon-Soo Ha, Eun-Taek Han, Seok-Ho Hong, Young Min Bae, Dong Ryeol Ryu, Won Sun Park. The anticholinergic drug oxybutynin inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells. Clinical and experimental pharmacology & physiology. 2019 11; 46(11):1030-1036. doi: 10.1111/1440-1681.13138. [PMID: 31330060]
  • Katja Walpurgis, Anja B Scheiff, Meike Welz, Jutta Müller-Reul, Nick Webborn, Christian Görgens, Sven Guddat, Gregor Fußhöller, Josef Dib, Mario Thevis. Pilot study on the effects of intravesical oxybutynin hydrochloride instillations on the validity of doping control urine samples. Drug testing and analysis. 2019 Nov; 11(11-12):1755-1760. doi: 10.1002/dta.2705. [PMID: 31670462]
  • Yongzhi Tian, Yongqing Wen, Jinghan Sun, Longshan Zhao, Zhili Xiong, Feng Qin. Simultaneous quantification of oxybutynin and its active metabolite N-desethyl oxybutynin in rat plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of oxybutynin transdermal patch. Biomedical chromatography : BMC. 2019 Apr; 33(4):e4456. doi: 10.1002/bmc.4456. [PMID: 30536598]
  • Silvio Aprile, Rossana Canavesi, Rosanna Matucci, Cristina Bellucci, Erika Del Grosso, Giorgio Grosa. New insights in the metabolism of oxybutynin: evidence of N-oxidation of propargylamine moiety and rearrangement to enaminoketone. Xenobiotica; the fate of foreign compounds in biological systems. 2018 May; 48(5):478-487. doi: 10.1080/00498254.2017.1342288. [PMID: 28608746]
  • Luise Borch, Soeren Hagstroem, Konstantinos Kamperis, C V Siggaard, Soeren Rittig. Transcutaneous Electrical Nerve Stimulation Combined with Oxybutynin is Superior to Monotherapy in Children with Urge Incontinence: A Randomized, Placebo Controlled Study. The Journal of urology. 2017 08; 198(2):430-435. doi: 10.1016/j.juro.2017.03.117. [PMID: 28327453]
  • Joe Hong, Jooyeon Lee, Holly Totouom-Tangho, Norma Ramos Dunn, Ronnie Gorman Swift. Methadone-Induced Hyperhidrosis Treated With Oxybutynin. Journal of addiction medicine. 2017 May; 11(3):237-238. doi: 10.1097/adm.0000000000000300. [PMID: 28244893]
  • A Fukata, T Yamazaki. Comparative Influence of Imidafenacin and Oxybutynin on Voiding Function in Rats with Functional Urethral Obstruction. Drug research. 2016 Jun; 66(6):306-11. doi: 10.1055/s-0035-1569410. [PMID: 26979753]
  • Yoshihiko Ito, Michishi Kashiwabara, Akira Yoshida, Eriko Hikiyama, Satomi Onoue, Shizuo Yamada. Muscarinic Receptor Binding in Rat Bladder Urothelium and Detrusor Muscle by Intravesical Solifenacin. Biological & pharmaceutical bulletin. 2016; 39(7):1167-71. doi: 10.1248/bpb.b16-00194. [PMID: 27374291]
  • Pasi Lampela, Teemu Paajanen, Sirpa Hartikainen, Risto Huupponen. Central Anticholinergic Adverse Effects and Their Measurement. Drugs & aging. 2015 Dec; 32(12):963-74. doi: 10.1007/s40266-015-0321-6. [PMID: 26518014]
  • Martien Humblet, Carla Verpoorten, Maria-Helena Christiaens, Herbert Hirche, Katrien Jansen, Gunnar Buyse, Jan D van Gool. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourology and urodynamics. 2015 Apr; 34(4):336-42. doi: 10.1002/nau.22560. [PMID: 24436114]
  • Nikolaj Rittig, Søren Hagstroem, Birgitte Mahler, Konstantinos Kamperis, Charlotte Siggaard, Mette Marie Mikkelsen, Wendy Fiona Bower, Jens C Djurhuus, Søren Rittig. Outcome of a standardized approach to childhood urinary symptoms-long-term follow-up of 720 patients. Neurourology and urodynamics. 2014 Jun; 33(5):475-81. doi: 10.1002/nau.22447. [PMID: 23765698]
  • H Kapoor, E Gupta, A Sood. Chronic pelvic ischemia: etiology, pathogenesis, clinical presentation and management. Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 2014 Jun; 66(2):127-37. doi: ". [PMID: 24988204]
  • Imran Ali, Zeid A Al-Othman, Abdulrahman Al-Warthan, Syed Dilshad Alam, Javed A Farooqi. Enantiomeric separation and simulation studies of pheniramine, oxybutynin, cetirizine, and brinzolamide chiral drugs on amylose-based columns. Chirality. 2014 Mar; 26(3):136-43. doi: 10.1002/chir.22276. [PMID: 24464520]
  • Primal Sharma, Daxesh P Patel, Mallika Sanyal, Swati Guttikar, Pranav S Shrivastav. Parallel achiral-chiral determination of oxybutynin, N-desethyl oxybutynin and their enantiomers in human plasma by LC-MS/MS to support a bioequivalence trial. Journal of pharmaceutical and biomedical analysis. 2014 Jan; 88(?):81-91. doi: 10.1016/j.jpba.2013.08.032. [PMID: 24036364]
  • Petra Krause, Uwe Fuhr, Jörg Schnitker, Uwe Albrecht, Raimund Stein, Peter Rubenwolf. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. The Journal of urology. 2013 Nov; 190(5):1791-7. doi: 10.1016/j.juro.2013.05.011. [PMID: 23669567]
  • Primal Sharma, Daxesh P Patel, Mallika Sanyal, Hiren Berawala, Swati Guttikar, Pranav S Shrivastav. Simultaneous analysis of oxybutynin and its active metabolite N-desethyl oxybutynin in human plasma by stable isotope dilution LC-MS/MS to support a bioequivalence study. Journal of pharmaceutical and biomedical analysis. 2013 Oct; 84(?):244-55. doi: 10.1016/j.jpba.2013.06.024. [PMID: 23867086]
  • Toshiki Hatanaka, Masashi Ukai, Mai Watanabe, Akiyoshi Someya, Akiyoshi Ohtake, Masanori Suzuki, Koji Ueshima, Shuichi Sato, Seiji Kaku. Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn-Schmiedeberg's archives of pharmacology. 2013 Jan; 386(1):71-8. doi: 10.1007/s00210-012-0814-3. [PMID: 23224420]
  • V Schuler, K Suter, K Fürer, D Eberli, M Horst, C Betschart, R Brenneisen, M Hamburger, M Mennet, M Schnelle, A P Simões-Wüst, U von Mandach. Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips--a pharmacological study towards a new treatment option of overactive bladder. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2012 Jul; 19(10):947-51. doi: 10.1016/j.phymed.2012.05.003. [PMID: 22824522]
  • Thomas Guttuso. Effective and clinically meaningful non-hormonal hot flash therapies. Maturitas. 2012 May; 72(1):6-12. doi: 10.1016/j.maturitas.2012.01.023. [PMID: 22377187]
  • Aniruddh V Deshpande, Patrina H Y Caldwell. Medical management of nocturnal enuresis. Paediatric drugs. 2012 Apr; 14(2):71-7. doi: 10.2165/11594870-000000000-00000. [PMID: 22168597]
  • Ernesto Callegari, Bimal Malhotra, Peter J Bungay, Rob Webster, Katherine S Fenner, Sarah Kempshall, Jennifer L LaPerle, Martin C Michel, Gary G Kay. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. British journal of clinical pharmacology. 2011 Aug; 72(2):235-46. doi: 10.1111/j.1365-2125.2011.03961.x. [PMID: 21392072]
  • Hiroshi Nagabukuro, Katherine L Villa, L Alexandra Wickham, Alison A Kulick, Loise Gichuru, Marcie J Donnelly, Gregory O Voronin, Tony Pereira, Xinchun Tong, Andrew Nichols, Stephen E Alves, Gary P O'Neill, Christopher V Johnson, Emily J Hickey. Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents. The Journal of pharmacology and experimental therapeutics. 2011 Jul; 338(1):220-7. doi: 10.1124/jpet.111.179747. [PMID: 21459965]
  • Stine Mjåvatn Jakobsen, Hege Kersten, Espen Molden. Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. Journal of the American Geriatrics Society. 2011 Mar; 59(3):501-5. doi: 10.1111/j.1532-5415.2010.03307.x. [PMID: 21391941]
  • Birger Wenge, Joachim Geyer, Heinz Bönisch. Oxybutynin and trospium are substrates of the human organic cation transporters. Naunyn-Schmiedeberg's archives of pharmacology. 2011 Feb; 383(2):203-8. doi: 10.1007/s00210-010-0590-x. [PMID: 21212936]
  • Shizuo Yamada, Masanao Seki, Masaki Ogoda, Ayako Fukata, Miho Nakamura, Yoshihiko Ito. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder. The Journal of pharmacology and experimental therapeutics. 2011 Feb; 336(2):365-71. doi: 10.1124/jpet.110.172288. [PMID: 21047953]
  • Roger R Dmochowski, Diane K Newman, Peter K Sand, Delbert C Rudy, Kim E Caramelli, Heather Thomas, Gary Hoel. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clinical drug investigation. 2011; 31(8):559-571. doi: 10.2165/11588990-000000000-00000. [PMID: 21721591]
  • Hiroshi Nagabukuro, Amanda Degenhardt, Katherine L Villa, Shruti L Mistry, Loise Gichuru, Nina Jochnowitz, Catherine Abbadie. Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats. Autonomic neuroscience : basic & clinical. 2010 Aug; 156(1-2):19-26. doi: 10.1016/j.autneu.2010.02.006. [PMID: 20335078]
  • D R Staskin, S Salvatore. Oxybutynin topical and transdermal formulations: an update. Drugs of today (Barcelona, Spain : 1998). 2010 Jun; 46(6):417-25. doi: 10.1358/dot.2010.46.6.1487750. [PMID: 20571610]
  • Ayesha Saleem. In women with urinary incontinence how necessary is cystometry?. JPMA. The Journal of the Pakistan Medical Association. 2010 May; 60(5):356-9. doi: NULL. [PMID: 20527606]
  • Jean-Jacques Wyndaele. Pediatrics: combining antimuscarinics shows promise for overactive bladder. Nature reviews. Urology. 2010 Feb; 7(2):66-8. doi: 10.1038/nrurol.2010.1. [PMID: 20145662]
  • David R Staskin, Dudley Robinson. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert opinion on pharmacotherapy. 2009 Dec; 10(18):3103-11. doi: 10.1517/14656560903451682. [PMID: 19954278]
  • Michael J Kennelly, Gary E Lemack, Jenelle E Foote, Cynthia S Trop. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009 Oct; 74(4):741-5. doi: 10.1016/j.urology.2009.05.008. [PMID: 19628264]
  • Patrick C Cartwright, Douglas E Coplen, Barry A Kogan, Weining Volinn, Eileen Finan, Gary Hoel. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. The Journal of urology. 2009 Oct; 182(4):1548-54. doi: 10.1016/j.juro.2009.06.058. [PMID: 19683731]
  • Stéphane Bolduc, Katherine Moore, Sylvie Lebel, Pascale Lamontagne, Micheline Hamel. Double anticholinergic therapy for refractory overactive bladder. The Journal of urology. 2009 Oct; 182(4 Suppl):2033-8. doi: 10.1016/j.juro.2009.05.099. [PMID: 19695628]
  • Peter K Sand. The evolution of transdermal therapy for overactive bladder. Current urology reports. 2009 Sep; 10(5):338-41. doi: 10.1007/s11934-009-0053-4. [PMID: 19709479]
  • Yoshihiko Ito, Luvsandorj Oyunzul, Akira Yoshida, Tomomi Fujino, Yukiko Noguchi, Hironori Yuyama, Akiyoshi Ohtake, Masanori Suzuki, Masao Sasamata, Minoru Matsui, Shizuo Yamada. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. European journal of pharmacology. 2009 Aug; 615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. [PMID: 19446545]
  • Angela K Götz, Stephan W Reinhold, Alexander Szecsey, Bernhard Banas, Bernhard K Krämer. Severe anticholinergic drug-induced delirium in a young adult after renal transplantation. Transplant international : official journal of the European Society for Organ Transplantation. 2009 Feb; 22(2):249-50. doi: 10.1111/j.1432-2277.2008.00759.x. [PMID: 18786150]
  • Mohamed Heba, Nesrin Ramadan, Moustafa El-Laithy. Polymeric matrix membrane sensors for stability-indicating potentiometric determination of oxybutynin hydrochloride and flavoxate hydrochloride urogenital system drugs. Journal of AOAC International. 2008 Nov; 91(6):1318-30. doi: NULL. [PMID: 19202792]
  • Katsuaki Ito, Akihito Iwami, Hiromi Katsura, Masahiro Ikeda. Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. Naunyn-Schmiedeberg's archives of pharmacology. 2008 Jun; 377(4-6):483-90. doi: 10.1007/s00210-007-0197-z. [PMID: 17917716]
  • Manabu Mitobe, Hirotaka Inoue, Timothy D Westfall, Hiroyuki Higashiyama, Kaori Mizuyachi, Hiroshi Kushida, Mine Kinoshita. A new method for producing urinary bladder hyperactivity using a non-invasive transient intravesical infusion of acetic acid in conscious rats. Journal of pharmacological and toxicological methods. 2008 May; 57(3):188-93. doi: 10.1016/j.vascn.2007.12.001. [PMID: 18367412]
  • Fayez Almodhen, Jean Paul Capolicchio, Roman Jednak, Mohamed El Sherbiny. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele. The Journal of urology. 2007 Oct; 178(4 Pt 1):1479-82. doi: 10.1016/j.juro.2007.05.171. [PMID: 17706702]
  • Pritam Kanagale, Braj Bhushan Lohray, Ambikanandan Misra, Prakash Davadra, Rajesh Kini. Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin. AAPS PharmSciTech. 2007 Jul; 8(3):E53. doi: 10.1208/pt0803053. [PMID: 17915803]
  • M Zaffanello, L Giacomello, M Brugnara, V Fanos. Therapeutic options in childhood nocturnal enuresis. Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 2007 Jun; 59(2):199-205. doi: . [PMID: 17571056]
  • Haruhi Mizushima, Kazuya Kinoshita, Koji Abe, Hitoshi Ishizuka, Yasuhiko Yamada. Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats. Biological & pharmaceutical bulletin. 2007 May; 30(5):955-62. doi: 10.1248/bpb.30.955. [PMID: 17473442]
  • Louise Cole, Charles Heard. Skin permeation enhancement potential of Aloe Vera and a proposed mechanism of action based upon size exclusion and pull effect. International journal of pharmaceutics. 2007 Mar; 333(1-2):10-6. doi: 10.1016/j.ijpharm.2006.09.047. [PMID: 17088033]
  • Joseph L Reiz, Paulette Salem, Andrew C Darke. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. Journal of clinical pharmacology. 2007 Mar; 47(3):351-7. doi: 10.1177/0091270006297226. [PMID: 17322147]
  • H Mizushima, K Takanaka, K Abe, I Fukazawa, H Ishizuka. Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica; the fate of foreign compounds in biological systems. 2007 Jan; 37(1):59-73. doi: 10.1080/00498250600976088. [PMID: 17178634]
  • Kyle J Van Arendonk, Matthew J Knudson, J Christopher Austin, Christopher S Cooper. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. Urology. 2006 Oct; 68(4):862-5. doi: 10.1016/j.urology.2006.04.034. [PMID: 17070368]
  • Osamu Maruyama, Yoshio Kawachi, Kisaburo Hanazawa, Kazuo Koizumi, Ryo Yamashita, Sosuke Sugimura, Shin-ichi Honda, Yoshiki Sugiyama, Toshihiko Saitoh, Kensho Noto. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. International journal of urology : official journal of the Japanese Urological Association. 2006 Oct; 13(10):1280-5. doi: 10.1111/j.1442-2042.2006.01538.x. [PMID: 17010005]
  • Hitoshi Kontani, Tetsukazu Hamamoto, Sunao Takeuchi, Yukari Nomura, Hiroyuki Sawanishi, Haruo Saito. Comparison of the effects of percutaneous and intraduodenal administration of oxybutynin on bladder contraction and salivation in rabbits. International journal of urology : official journal of the Japanese Urological Association. 2006 Jul; 13(7):977-84. doi: 10.1111/j.1442-2042.2006.01451.x. [PMID: 16882066]
  • Kyle J Van Arendonk, J Christopher Austin, Margaret A Boyt, Christopher S Cooper. Frequency of wetting is predictive of response to anticholinergic treatment in children with overactive bladder. Urology. 2006 May; 67(5):1049-53; discussion 1053. doi: 10.1016/j.urology.2005.11.060. [PMID: 16698366]
  • Bariş Nuhoğlu, Vecihi Fidan, Ali Ayyildiz, Erim Ersoy, Cankon Germiyanoğlu. Stoller afferent nerve stimulation in woman with therapy resistant over active bladder; a 1-year follow up. International urogynecology journal and pelvic floor dysfunction. 2006 May; 17(3):204-7. doi: 10.1007/s00192-005-1370-x. [PMID: 16049624]
  • Tomomi Oki, Ayako Toma-Okura, Shizuo Yamada. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. The Journal of pharmacology and experimental therapeutics. 2006 Mar; 316(3):1137-45. doi: 10.1124/jpet.105.094508. [PMID: 16282521]
  • Yongtae Kim, Naoki Yoshimura, Hitoshi Masuda, Fernando De Miguel, Michael B Chancellor. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU international. 2006 Feb; 97(2):400-3. doi: 10.1111/j.1464-410x.2005.05913.x. [PMID: 16430654]
  • G Willy Davila. Transdermal oxybutynin in the treatment of overactive bladder. Clinical interventions in aging. 2006; 1(2):99-105. doi: 10.2147/ciia.2006.1.2.99. [PMID: 18044106]
  • Masaru Sakaguchi, Kazuhiro Goto, Hiroyuki Ichiki, Naoko Hattori, Akira Iizuka, Masahiro Yamamoto, Shuichi Takeda, Atsushi Ishige, Masaki Aburada, Masako Yasuda, Toshinori Yamamoto. Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats. Journal of ethnopharmacology. 2005 Nov; 102(2):164-9. doi: 10.1016/j.jep.2005.05.049. [PMID: 16055291]
  • Sung-Hee Cho, Hun-Woo Lee, Ho-Taek Im, Wan-Su Park, Minsun Baek, Kyung-Tae Lee. Quantification of propiverine by liquid chromatography/electrospray tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy subjects. Journal of pharmaceutical and biomedical analysis. 2005 Sep; 39(3-4):670-6. doi: 10.1016/j.jpba.2005.03.038. [PMID: 15936164]
  • Tomomi Oki, Shuichi Sato, Keiji Miyata, Shizuo Yamada. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. British journal of pharmacology. 2005 May; 145(2):219-27. doi: 10.1038/sj.bjp.0706184. [PMID: 15753946]
  • Tomomi Oki, Akihiro Kawashima, Masayuki Uchida, Shizuo Yamada. In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin. Life sciences. 2005 Apr; 76(21):2445-56. doi: 10.1016/j.lfs.2004.11.013. [PMID: 15763076]
  • YongTae Kim, Naoki Yoshimura, Hitoshi Masuda, Fernando de Miguel, Michael B Chancellor. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005 Feb; 65(2):238-42. doi: 10.1016/j.urology.2004.11.021. [PMID: 15708029]
  • R Luque Mialdea, R Martín-Crespo, E Hernández, O Sánchez, A Cañizo, A Fernández, C Aparicio, T Blanco, J Cebrían. [Use of oral anticholinergic therapy in children under 1 years of age with high risk bladder]. Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica. 2005 Jan; 18(1):3-7. doi: NULL. [PMID: 15901100]
  • Israel Franco, Mark Horowitz, Richard Grady, Richard C Adams, Tom P V M de Jong, Kelly Lindert, Detlef Albrecht. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. The Journal of urology. 2005 Jan; 173(1):221-5. doi: 10.1097/01.ju.0000147813.28822.d2. [PMID: 15592080]
  • K Giannitsas, P Perimenis, A Athanasopoulos, K Gyftopoulos, G Nikiforidis, G Barbalias. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. European urology. 2004 Dec; 46(6):776-82; discussion 782. doi: 10.1016/j.eururo.2004.07.021. [PMID: 15548447]
  • Daniela Marschall-Kehrel. Update on nocturia: the best of rest is sleep. Urology. 2004 Dec; 64(6 Suppl 1):21-4. doi: 10.1016/j.urology.2004.10.072. [PMID: 15621224]
  • Tomomi Oki, Ryohei Kimura, Motoaki Saito, Ikuo Miyagawa, Shizuo Yamada. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. The Journal of urology. 2004 Nov; 172(5 Pt 1):2059-64. doi: 10.1097/01.ju.0000138472.16876.8d. [PMID: 15540789]
  • Michael Preik, Detlef Albrecht, Martin O'Connell, Christian Hampel, Rodney Anderson. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. BJU international. 2004 Oct; 94(6):821-7. doi: 10.1111/j.1464-410x.2004.05040.x. [PMID: 15476516]
  • Archana Puri, Minu Bajpai, Arun K Gupta. Bilateral spontaneous perinephric urinomas: case report and review of the literature. Urology. 2004 Sep; 64(3):590-1. doi: 10.1016/j.urology.2004.04.057. [PMID: 15351610]
  • Nelson Bennett, Margie O'Leary, Ankur S Patel, Macrina Xavier, Janet R Erickson, Michael B Chancellor. Can higher doses of oxybutynin improve efficacy in neurogenic bladder?. The Journal of urology. 2004 Feb; 171(2 Pt 1):749-51. doi: 10.1097/01.ju.0000103274.38694.b1. [PMID: 14713802]
  • Gayatri Sathyan, Roger R Dmochowski, Rodney A Appell, Cindy Guo, Suneel K Gupta. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. Clinical pharmacokinetics. 2004; 43(14):1059-68. doi: 10.2165/00003088-200443140-00008. [PMID: 15530134]
  • M Asif A Siddiqui, Caroline M Perry, Lesley J Scott. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004; 64(8):885-912. doi: 10.2165/00003495-200464080-00011. [PMID: 15059046]
  • Eric S Rovner. Trospium chloride in the management of overactive bladder. Drugs. 2004; 64(21):2433-46. doi: 10.2165/00003495-200464210-00005. [PMID: 15482001]
  • Y Homma, J S Paick, J G Lee, K Kawabe. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU international. 2003 Nov; 92(7):741-7. doi: 10.1046/j.1464-410x.2003.04468.x. [PMID: 14616458]
  • R Martín-Crespo, R Luque. [In which patients is the oxybutynin-desmopressin combination therapy indicated?]. Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica. 2003 Oct; 16(4):181-5. doi: NULL. [PMID: 14677356]
  • Rodney A Appell, Michael B Chancellor, R Howard Zobrist, Heather Thomas, Steven W Sanders. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clinic proceedings. 2003 Jun; 78(6):696-702. doi: 10.4065/78.6.696. [PMID: 12934778]
  • Hohyun Kim, Sang Beom Han. Sensitive determination of oxybutynin and desethyloxybutynin in dog plasma by LC-ESI/MS/MS. Journal of pharmaceutical and biomedical analysis. 2003 Feb; 31(2):341-9. doi: 10.1016/s0731-7085(02)00644-1. [PMID: 12609673]
  • R Howard Zobrist, Danyi Quan, Heather M Thomas, Stephanie Stanworth, Steven W Sanders. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharmaceutical research. 2003 Jan; 20(1):103-9. doi: 10.1023/a:1022259011052. [PMID: 12608543]
  • Lynne M Bang, Stephanie E Easthope, Caroline M Perry. Transdermal oxybutynin: for overactive bladder. Drugs & aging. 2003; 20(11):857-64. doi: 10.2165/00002512-200320110-00007. [PMID: 12964892]
  • Roger R Dmochowski, David R Staskin. Advances in drug delivery: improved bioavailability and drug effect. Current urology reports. 2002 Dec; 3(6):439-44. doi: 10.1007/s11934-002-0094-4. [PMID: 12425864]
  • S De Wachter, A Vermandel, K De Moerloose, J J Wyndaele. Value of increase in bladder capacity in treatment of refractory monosymptomatic nocturnal enuresis in children. Urology. 2002 Dec; 60(6):1090-4. doi: 10.1016/s0090-4295(02)02127-1. [PMID: 12475676]
  • Alan D Garely, Lara J Burrows. Current pharmacotherapeutic strategies for overactive bladder. Expert opinion on pharmacotherapy. 2002 Jul; 3(7):827-33. doi: 10.1517/14656566.3.7.827. [PMID: 12083983]
  • A M K Rickwood. Assessment and conservative management of the neuropathic bladder. Seminars in pediatric surgery. 2002 May; 11(2):108-19. doi: 10.1053/spsu.2002.31810. [PMID: 11973763]
  • Akimasa Shibukawa, Nobuko Ishizawa, Tomoko Kimura, Yuki Sakamoto, Kanae Ogita, Yuka Matsuo, Yukihiro Kuroda, Chutima Matayatsu, Terumichi Nakagawa, Irving W Wainer. Plasma protein binding study of oxybutynin by high-performance frontal analysis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Feb; 768(1):177-88. doi: 10.1016/s0378-4347(01)00497-2. [PMID: 11939551]
  • Kari Lehtoranta, Hanna Tainio, Eeva Lukkari-Lax, Tiina Hakonen, Teuvo L J Tammela. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scandinavian journal of urology and nephrology. 2002 Feb; 36(1):18-24. doi: 10.1080/003655902317259319. [PMID: 12002352]
  • S M Di Stasi, A Giannantoni, P Navarra, G Capelli, L Storti, M Porena, R L Stephen. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. The Journal of urology. 2001 Dec; 166(6):2232-6. doi: 10.1016/s0022-5347(05)65540-1. [PMID: 11696741]
  • J H Evans. Evidence based management of nocturnal enuresis. BMJ (Clinical research ed.). 2001 Nov; 323(7322):1167-9. doi: 10.1136/bmj.323.7322.1167. [PMID: 11711411]
  • C Crandall. Tolterodine: a clinical review. Journal of women's health & gender-based medicine. 2001 Oct; 10(8):735-43. doi: 10.1089/15246090152636488. [PMID: 11703885]
  • G Sathyan, M B Chancellor, S K Gupta. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. British journal of clinical pharmacology. 2001 Oct; 52(4):409-17. doi: 10.1046/j.0306-5251.2001.01463.x. [PMID: 11678784]
  • T Oka, K Nakano, T Kirimoto, N Matsuura. Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats. Japanese journal of pharmacology. 2001 Sep; 87(1):27-33. doi: 10.1254/jjp.87.27. [PMID: 11676195]
  • J H Evans. Nocturnal enuresis. The Western journal of medicine. 2001 Aug; 175(2):108-11. doi: 10.1136/ewjm.175.2.108. [PMID: 11483553]
  • R H Zobrist, B Schmid, A Feick, D Quan, S W Sanders. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharmaceutical research. 2001 Jul; 18(7):1029-34. doi: 10.1023/a:1010956832113. [PMID: 11496941]
  • S M Di Stasi, A Giannantoni, G Vespasiani, P Navarra, G Capelli, R Massoud, R L Stephen. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. The Journal of urology. 2001 Feb; 165(2):491-8. doi: 10.1097/00005392-200102000-00032. [PMID: 11176403]